Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results
As dueling data emerge between their drug ivonescimab and a rival Merck medication, Summit and Akeso revealed new findings that impressed Wall Street.
Useful takeaways from this story.
As dueling data emerge between their drug ivonescimab and a rival Merck medication, Summit and Akeso revealed new findings that impressed Wall Street.
Building the complete brief
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
The useful part
As dueling data emerge between their drug ivonescimab and a rival Merck medication, Summit and Akeso revealed new findings that impressed Wall Street.
Keep reading in the app
Open the app view to save this story, compare related coverage, and continue from the same source.